Date:2/15/2008

cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact PAREXEL's recognition of revenue included in backlog; PAREXEL's dependence on certain industries and clients; PAREXEL's ability to win new business, manage growth and costs, and attract and retain employees; PAREXEL's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on PAREXEL's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of PAREXEL's Quarterly Report on Form 10-Q for the period ended December 31, 2007 as filed with the SEC on February 7, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward- looking statements included in this press release represent PAREXEL's estimates as of the date of this release. PAREXEL specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing PAREXEL's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
'/>"/>

SOURCE PAREXEL International Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related biology technology :

1. Genmab A/S - Company Announcement
2. Advanced Life Sciences to Host Conference Call to Discuss Announcement Made Yesterday by FDA to Conduct Advisory Panel on CAP Drug Development
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Leading Pharmaceutical Communication Executives Gather for the 1st Annual Pharmaceutical Public Relations Symposium
5. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
6. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
7. China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
8. China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
9. Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions
10. International Human Rights Day Recognized by Terasem Movement, Inc.s Third Annual Colloquium on the Law of Transbeman Persons
11. Siemens Building Technologies Helping Companies Participate in EPA Labs21 Movement With Comprehensive Compliance Solution Strategy